- Molecular NameLansoprazole
- SynonymAG 1749; lansoprazole
- Weight369.367
- Drugbank_IDDB00448
- ACS_NO103577-45-3
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)2.82
- pka3.9
- LogD (pH=7, predicted)2.82
- Solubility (experiment)0.03 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-4.87
- LogSw (predicted, AB/LogsW2.0)0.12
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors1
- No.of HBond Acceptors5
- No.of Rotatable Bonds6
- TPSA87.08
- StatusFDA approved
- AdministrationOral, IV
- PharmacologyA proton-pump inhibitor (PPI) which prevents the stomach from producing gastric acid.
- Absorption_value85.0
- Absorption (description)Lansoprazole is rapidly absorbed after oral administration and peak plasma concentrations are reached within approx. 1.5 h.
- Caco_2N/A
- Bioavailability81.0
- Protein binding97.0
- Volume of distribution (VD)0.35 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe drug is extensively metabolised in the liver to its sulfide and sulfone metabolites, and the 5-hydroxy metabolites of these.
- Half life0.90 h
- ExcretionThe drug and its metabolites, in the form of glucuronides, are excreted mainly in faeces via bile with 15 to 30% of an administered dose in urine. No unchanged drug has been detected. Clearance is reduced in elderly patients and in those with liver disease.
- Urinary Excretion<1
- Clerance6.23 ml/min/kg
- ToxicitySymptoms of overdose include abdominal pain, nausea and diarrhea.
- LD50 (rat)N/A
- LD50 (mouse)N/A